Tenders of Dak Gesundheit

Germany – Pharmaceutical Products – Abschluss Einer Nicht-exklusiven Rabattvereinbarung Nach § 130a Absatz 8 Sgb V Zum Wirkstoff Sofosbuvir Und Velpatasvir, Atc J05ap55 Für Die Zeit 01.05.2024 - 30.04.2026

Germany – Pharmaceutical Products – Abschluss Einer Nicht-exklusiven Rabattvereinbarung Nach § 130a Absatz 8 Sgb V Zum Wirkstoff Benazepril + Hydrochlorothiazid, Atc C09ba27 Für Die Zeit 01.03.2024 - 28.02.2026

Germany-hamburg: Pharmaceutical Products

Supporting Customer Management in the Implementation of Automation and Digitization of Customer Contacts

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 Sgb V for the active ingredient Clobetasol, Atc D07ad01 for the period December 1st, 2023 - November 30th, 2025 (1004083 - Clobetasol, Atc D07ad01)

Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 SGB V for the active ingredient Vericiguat, Atc C01dx22 for the period November 1st, 2023 - October 31st, 2025

Germany-hamburg: Pharmaceutical Products

Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient tacrolimus, ATC L04ad02 (obo) for the period 01.09.2024 - 31.08.2025 (plus extension option 1x12 months)

Germany-hamburg: Pharmaceutical Products

Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 Sgb V for the active ingredient Natalizumab (exclusively in the Dafo infusion solution concentrate), Atc L04aa23 for the period December 1st, 2023-November 30th, 2025 (1004084 - Natalizumab (exclusively in the kiln